The specimen is part of the interpretation
Blood is a convenient source of DNA for hereditary cancer testing, but a result from blood does not automatically establish that a variant is constitutional. Acquired changes in blood-forming cells can involve the same genes that cause inherited cancer predisposition. The clinical question therefore includes both what the variant means and where it is present. NCI’s professional summary describes this overlap.
Clonal haematopoiesis involves expansion of blood-forming cells sharing an acquired genetic change. In hereditary cancer assessment, TP53 illustrates why this matters: a blood finding may reflect constitutional variation, postzygotic mosaicism, or an acquired blood-cell population. These possibilities carry different implications. GeneReviews discusses the differential interpretation.
Separate pathogenicity from origin
A pathogenic classification addresses evidence that a variant can cause disease in a defined context. It does not, by itself, establish that the change was inherited or is present throughout the person’s tissues. A useful interpretation keeps these questions separate rather than allowing the classification label to answer both.
For TP53, low-level detection in leukocytes can suggest an acquired process, including clonal haematopoiesis of indeterminate potential, or CHIP. Other explanations include haematological malignancy or premalignancy and circulating tumour cells. Conversely, an acquired TP53 variant can occur at an allele frequency resembling a constitutional heterozygous finding. Frequency alone cannot settle origin. GeneReviews explains these limitations.
Choose a specimen that answers the question
Changing the collection method does not necessarily change the biological source. Saliva and buccal samples contain white blood cells. In people with haematological malignancy, these cells can carry somatic variants that complicate germline interpretation. A second sample therefore needs a clear purpose: repeating detection and investigating tissue distribution are different tasks.
Cultured skin fibroblasts are commonly used to obtain non-haematopoietic DNA for hereditary haematological malignancy assessment. Collection, culture and testing require planning. After allogeneic haematopoietic stem-cell transplantation, blood and buccal specimens can contain donor DNA, making specimen history particularly important. NCI describes specimen selection and transplant-related limitations.
Before further testing, the clinical team and laboratory can clarify three practical questions:
- Is the aim to confirm the sequence finding or determine its origin?
- Which accepted specimen best addresses that uncertainty?
- How will each possible result change the interpretation?
Avoid turning uncertainty into a family diagnosis
Confirming the origin of a finding matters because hereditary cancer results can influence surveillance, reproductive discussions and testing of relatives. Those consequences belong in counselling, including an explanation of what is established and what remains unresolved. NCI recognises that inconclusive blood or saliva results sometimes require testing a second tissue, such as skin. Its genetic testing fact sheet describes follow-up and counselling.
In the TP53 setting, a variant confirmed to result from blood-restricted clonal expansion does not establish Li-Fraumeni syndrome. Constitutional or early postzygotic TP53 mosaicism has different cancer-risk implications. Additional tissue testing and, in selected circumstances, testing relatives may help distinguish these explanations. GeneReviews outlines ancillary evaluation.
Clinical practice and research answer different questions
Established clinical practice includes interpreting results alongside personal and family history, explaining limitations, and arranging appropriate follow-up. An unresolved result should be communicated as unresolved. A negative or inconclusive genetic finding also does not erase a concerning clinical history. NCI explains why follow-up remains context dependent.
Research continues to refine understanding of inherited predisposition, acquired variants and their interactions. Findings from somatic sequencing can raise a germline question, but a tumour or myeloid panel is not a substitute for germline evaluation. For clinicians, the immediate task is to document the specimen, the remaining uncertainty and who will coordinate its resolution. NCI distinguishes these testing roles.